Ignite Creation Date:
2024-05-06 @ 3:45 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04743076
Status:
SUSPENDED
Last Update Posted:
2021-09-14
First Post:
2021-02-02
Brief Title:
A Randomized Trial Of Endovascular Treatment For Acute Posterior Large Vessel Occlusion
Sponsor:
Xinqiao Hospital of Chongqing
Organization:
Xinqiao Hospital of Chongqing
Study Overview
Official Title:
Standard Medical Treatment Plus Endovascular Treatment Versus Standard Medical Treatment Alone for Stroke Patient With Large Vessel Occlusion In The Posterior Circulation A Multicenter Randomized Clinical Trial
Status:
SUSPENDED
Status Verified Date:
2021-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Withdrawal of funding
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BASILAR-2
Brief Summary:
The aim of this trial is to investigate whether endovascular treatment can improve the 90-day functional outcome of acute large vessel occlusion in the posterior circulation
Detailed Description:
At least seven randomized controlled trials have consistently shown that endovascular treatment can improve the functional outcome of stroke patients with acute anterior large vessel occlusion However these trials did not include patients with large vessel occlusion in the posterior circulation
The hypothesis of this trial Compared with standard medical treatment alone standard medical treatment combined with endovascular treatment can significantly improve the 90-day functional outcome of acute large vessel occlusion in the posterior circulation
The hypothesis of this trial Compared with standard medical treatment alone standard medical treatment combined with endovascular treatment can significantly improve the 90-day functional outcome of acute large vessel occlusion in the posterior circulation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None